Contact information
merryn.voysey@paediatrics.ox.ac.uk
+44 (0)1865 611314
Oxford Vaccine Group, CCVTM, Churchill Rd, Headington, Oxford, OX3 7LE
Research groups
Merryn Voysey
Professor of Statistics in Vaccinology
Merryn Voysey is Professor of Statistics in Vaccinology at the Oxford Vaccine Group. She has extensive experience in leading vaccines research including clinical trials and observational studies, and was the lead methodologist for the Oxford-AstraZeneca vaccine trials.
Merryn is the Principal Investigator of a global study of measles seroprevalence in infants from 9 countries, and is Chief Investigator of a randomised controlled trial assessing the early administration of measles vaccination in Ugandan infants. With funding from the Bill & Melinda Gates Foundation, she is principal investigator of studies investigating the contribution of T-cell immunity to protection against SARS-CoV-2 infection, correlates of protection and vaccine efficacy for group B streptococcus vaccines, and a study of pneumococcal vaccine seroefficacy. In addition, she is co-investigator on the EDCTP3 funded PROTECT study: Preparing for Optimal Phase III/IV maternal Group B Streptococcal vaccine trials in Africa.
Merryn is a member of the WHO Technical Advisory Group on Group B Streptococcus Vaccine Development, the UK JCVI Subcommittee on GBS Vaccines, and the NIHR Health Technology Assessment Funding Committee. Additionally she chairs the Department of Paediatrics Athena Swan Data subcommittee.
In 2022 Merryn was awarded Australian of the Year in the UK by the Australian High Commission and was a guest of the Australian Government at Westminster Abbey for the Coronation of King Charles III.
Key publications
-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Voysey M. et al, (2021), Lancet, 397, 99 - 111
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M. et al, (2021), Lancet, 397, 881 - 891
-
Serotype-Specific Correlates of Protection for Pneumococcal Carriage: An Analysis of Immunity in 19 Countries.
Voysey M. et al, (2018), Clin Infect Dis, 66, 913 - 920
-
The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses : An Individual Participant Meta-analysis.
Voysey M. et al, (2017), JAMA Pediatr, 171, 637 - 646
Recent publications
-
Epidemiology of Group B Streptococcus: Maternal Colonization and Infant Disease in Kampala, Uganda
Kyohere M. et al, (2025), Open Forum Infectious Diseases
-
Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities.
El Safadi D. et al, (2025), J Infect Dis, 231, e17 - e27
-
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
Feng S. et al, (2025), J Infect, 90
-
Mass testing for discovery and control of COVID-19 outbreaks in adult social care: an observational study and cost-effectiveness analysis of 14 805 care homes in England.
Chen S. et al, (2025), BMJ Public Health, 3
-
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
Conlin K. et al, (2024), Vaccine, 45